Research No Longer Recruiting Patients

The research studies listed below are no longer recruiting patients.

If you have questions about any of the research studies listed below, please leave a voicemail for our research team at 206-320-2200.

ARBACLOFEN

A Randomized, Double Blind, Placebo-Controlled Efficacy and Safety Study of Arbaclofen Placarbil in Subjects with Spasticity due to Multiple Sclerosis

Sponsor:  Xenoport

Type of MS:  All types

Contact:  Caryl Tongco, (206) 215-3565

Wellness

Multiple Sclerosis Wellness Protocol

Sponsor: None

Types of MS: All types

OPERA WA21903

A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sclerosis

Sponsor: Roche Gententech

Type of MS: Relapsing-Remitting

Contact: Yuriko Courtney 206-320-2647

DioGenix Specificity Study

Differential Gene Expression Profiling in the Blood of Patients with Multiple Sclerosis and MS Mimics

Sponsor: DioGenix

Types of MS: Relapsing-Remitting, Secondary-Progressive

DioGenix Steroid Study

DifferTemporal Gene Expression and microRNA Profiling in the Blood of Patients with Demyelinating Disease Treated with Steroids ential Gene Expression Profiling in the Blood of Patients with Multiple Sclerosis and MS Mimics

Sponsor: DioGenix

Types of MS: Relapsing-Remitting, Clinically Isolated Syndrome (CIS)

CARE-MS Extension

An extension protocol for multiple sclerosis patients who participated in Genzyme-sponsored studies of alemtuzumab.

Sponsor: Genzyme

Type of MS: Relapsing-Remitting

More Information

Tygris

Tysabri global observational program in safety

Sponsor: Biogen

More Information

BG12 Extension

A dose-blind, multicenter, extension study to determine the long-term safety and efficacy of two doses of BG00012 monotherapy in subjects with relapsing-remitting multiple sclerosis

Sponsor: Biogen

More Information

HALT-MS

A Phase II Study of High-Dose Immunosuppressive Therapy (HDIT) Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin, and Autologous CD34+ Hematopoietic Stem Cell Transplant (HCT) for the Treatment of Poor Prognosis Multiple Sclerosis

Sponsor: NIH

BAF Extension

A dose blinded extension study to the CBAF312A2201 study to evaluate long-term safety, tolerability and efficacy of BAF312 given orally once daily in patients with relapsing-remitting multiple sclerosis

Sponsor: Novartis

Type of MS: Relapsing-Remitting

More Information

STRATIFY

JCV antibody program in patients with relapsing multiple sclerosis receiving or considering treatment with Tysabri: Stratify-2

Sponsor: Biogen

Types of MS: Relapsing-Remitting

More Information